Compare HIMX & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HIMX | ZYME |
|---|---|---|
| Founded | 2001 | 2003 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | 2006 | 2022 |
| Metric | HIMX | ZYME |
|---|---|---|
| Price | $20.63 | $24.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $38.90 |
| AVG Volume (30 Days) | ★ 4.9M | 530.2K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.23% | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $105,965,000.00 |
| Revenue This Year | $14.94 | $183.10 |
| Revenue Next Year | $7.79 | N/A |
| P/E Ratio | $14.99 | ★ N/A |
| Revenue Growth | N/A | ★ 38.87 |
| 52 Week Low | $6.85 | $11.02 |
| 52 Week High | $21.80 | $29.75 |
| Indicator | HIMX | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 78.59 | 39.64 |
| Support Level | $7.63 | $22.28 |
| Resistance Level | N/A | $27.54 |
| Average True Range (ATR) | 1.44 | 1.28 |
| MACD | 0.89 | -0.52 |
| Stochastic Oscillator | 89.48 | 17.45 |
Himax Technologies Inc is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The majority of the firm's revenue is derived from the Driver Integrated Circuit segment. It offers display driver ICs and timing controllers used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, virtual reality (VR) devices, and many other consumer electronics devices. It also designs and provides controllers for touch sensor displays, in-cell Touch and Display Driver Integration single-chip solutions, LED driver ICs, power management ICs, and scaler products for monitors and projectors. Geographically, it generates the majority of its revenue from China.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.